Saturday 17 October 2026
Export INTS’s income statement to Excel — free account
Intensity Therapeutics Inc.
INTS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 65.9%, free cash flow grew 4.72% and total debt fell 34.7%, each against the same quarter a year earlier.
3.35
0.03
−0.89%
Follow INTS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (195.88%) | (207.37%) | (156.90%) | (234.70%) |
+8 more TTM periods Free account |
|
| (139.85%) | (139.27%) | (122.92%) | (158.62%) | ||
ROIC |
0.00% | 0.00% | (22,007.35%) | (3,108.21%) | |
Return on Tangible Assets |
(124.25%) | (123.42%) | (109.87%) | (198.58%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.31) | (3.58) | (6.81) | (5.52) | |
Free Cash Flow |
(8.95) | (9.07) | (9.23) | (9.50) | |
| Other line items | |||||
Cash ROIC |
(47.61%) | (44.69%) | (38.67%) | (66.08%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.80 | 0.85 | 0.80 | 0.81 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.31) | (3.58) | (6.81) | (5.52) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates